Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05733663
Other study ID # GFDL
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2013
Est. completion date December 31, 2020

Study information

Verified date April 2023
Source Hospital Mutua de Terrassa
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Coeliac disease (CD) is a systemic process of autoimmune nature related to the existence of a permanent intolerance to gluten and manifests itself in genetically susceptible individuals. It has a global prevalence of 0.5-1.5%. The diagnosis of CD should be made in patients following a normal gluten-containing diet and is based on coeliac serology and histopathological changes of the small intestinal mucosa. However, nowadays many patients come to their doctor to rule out CD after having started a gluten-free diet (GFD) with improvement of symptoms. In this scenario, making the diagnosis of CD remains a challenge, as it must be considered that most CD-associated changes revert after gluten withdrawal. An essential finding of CD is the increased number in total intraepithelial lymphocytes (IEL) in the duodenal mucosa, later characterized by an expansion of γδ+ and CD8+ IEL coupled to a decrease in CD3- IEL. An accurate quantification of the γδ+ subset became possible with the introduction of flow cytometry. In 2002, Spanish investigators proposed a diagnostic algorithm for paediatric CD that included the combined use of a high percentage of γδ+ and a low percentage of CD3- IEL, which was termed the coeliac lymphogram, which has been shown to be very accurate for the diagnosis of CD. Thus, the use of flow cytometric phenotyping of IEL may strengthen the diagnosis of CD when it is not straightforward. This study will provide information about the potential usefulness of T-cell flow cytometric coeliac patterns as CD biomarkers to confirm the diagnosis of CD in patients who have already started a GFD. These results may help to make decisions in specific situations of routine clinical practice, avoiding bothersome gluten reintroduction and delays in diagnosis.


Description:

Hypothesis: The increase in the TCRγδ+ subset appears to be permanent despite a GFD, which opens up the possibility of using it as a diagnostic tool in patients following a GFD, without the need to undergo gluten challenge. Several studies have focused on this aspect with promising results, but the studies have been performed on small samples of patients, and follow-up time after a GFD has not always been described or only changes in mean values before versus after the diet have been reported.


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date December 31, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria: - Paediatric or adult patients diagnosed with CD and started on a strict GFD - Patients with a follow-up intestinal biopsy to assess histological remission at least 1-year after starting the GFD - Assessment of the intraepithelial lymphogram at both baseline and follow-up - Presence of increased TCR?d+ cells at baseline. Exclusion criteria: - Refusal of the patient to participate in the registry. - Pregnancy and severe comorbidities (heart disease, chronic obstructive pulmonary disease, liver disease, bleeding disorders, etc). - Patients with intake of NSAIDs or Olmesartan. - Patients with Crohn's disease, autoimmune disease associated enteropathy, collagenous sprue, microscopic colitis, lymphocytic enteritis due to intestinal parasitosis or Helicobacter pylori infection, other enteropathies. - Selective IgA deficiency.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Endoscopic procedure with duodenal biopsy
In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated. T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCR?d+ IEL =8.5% (=mean + 2SD) and CD3- IEL =10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCR?d+ cells, and the coeliac lymphogram.

Locations

Country Name City State
Spain Hospital Universitari Mutua Terrassa Terrassa Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Mutua de Terrassa

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Frequency of persisting CD changes despite a GFD (i.e., positive CD serology, persistent villous atrophy) at the time of follow-up biopsy and compare them with the frequency of a persistent increase in ?d+ subset. 1 year
Primary Percentage of long-term persistence of both the coeliac lymphogram (increase in TCR?d+ and decrease in CD3- cells) and the isolated increase in TCR?d+ cells measured by T-cell flow cytometry in CD patients after starting a GFD. Lymphocyte subpopulations (TCR?d+ and CD3- cells) are measured by flow cytometry. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to baseline histology (measured by Marsh Classification: 0, 1, 2 or 3) To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to age group (measured by years). To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to gender (classified according to male or female sex). To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to coeliac serology (measured by presence or absence of anti-transglutaminase antibodies). To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to DQ-genotype (measured by presence or absence of HLA-DQ2.5). To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
Secondary Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to follow-up time (measured by years). To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. 1 year
See also
  Status Clinical Trial Phase
Completed NCT04349904 - Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Completed NCT04593251 - Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis Phase 1
Completed NCT05810441 - Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
Recruiting NCT05555446 - Bovine Colostrum to Prevent Absorption of Gluten Early Phase 1
Completed NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
Completed NCT01172665 - Celiac Disease Database
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Recruiting NCT05425446 - Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients Phase 1
Enrolling by invitation NCT02202681 - Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule N/A
Completed NCT00362856 - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects Phase 2
Terminated NCT03866538 - Budesonide in Patients With Immune Mediated Enteropathies Phase 4
Recruiting NCT05135923 - Glutenfree, Gut Microbiota and Metabolic Regulation N/A
Completed NCT05052164 - Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women N/A
Completed NCT03775499 - Probiotic BL NCC 2705 and Gluten Sensitivity N/A
Completed NCT03707730 - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease Phase 2